Clinical evaluation of oral administration of a cholecystokinin-A receptor antagonist (loxiglumide) to patients with acute, painful attacks of chronic pancreatitis: a multicenter dose-response study in Japan.

What Was Tested

This randomized controlled trial looks at Cholecystokinin (CCK) in the context of chronic pain: fibromyalgia & crps.

CCK appears to play an important role in the development and progression of acute pancreatitis, and the recent development of CCK antagonists has provided a new approach to the treatment of acute pancreatitis in humans.

Who Took Part

By PubMed's age tags, the people studied were adults and middle-aged adults, both men and women.

Chronic pancreatitis was diagnosed for all patients on the basis of the Japanese criteria for chronic pancreatitis.

The groups were comparable with respect to age, sex, etiology, complications, and previous treatment.

How the Study Was Run

In design terms this was a randomized, placebo-controlled and multicenter study.

Random assignment meant chance, not the researchers, decided who got Cholecystokinin (CCK) and who got the comparison, which limits bias.

A placebo (an inactive look-alike) gave the Cholecystokinin (CCK) group a baseline to be compared against.

Running at several centres spread the Cholecystokinin (CCK) study over different clinics and patient groups.

What Was Measured

The subject headings attached to it are Acute Disease, Amylases, Chronic Disease, Hormone Antagonists, Lipase, Pain and Pancreatitis.

What This Means in Plain Language

The paper is a randomized, placebo-controlled and multicenter study of Cholecystokinin (CCK) in people with chronic pain: fibromyalgia & crps.

Its findings take up roughly 4 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2002 (Pancreas), a journal based in United States.

More context: the Cholecystokinin (CCK) compound page, Chronic pain: fibromyalgia & CRPS research.